Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee.

TRANSFUSION1993—Vol. 33, No, 5FACTOR CONCENTRATES 1992433 12. Finlayson JS, Tankersley DL, Anti-HCV screening and plasmafractionation: the ease against (letter). Lancct 1990;335:1274-5.13. Pneumocystis carina pneumonia among persons with hemophiliaA . MMWR Morb Mortal Wkly Rep 1982;31:365-7.14. Krciss JK, Kitchen LW, Princc HE, Kasper CK, Essex M . An­tibody to human T-lymphotropic virus type III in wives of he­mophiliacs. Evidence for heterosexual transmission. Ann InternMed 1985;102:623-6.15. Ragni MV, Winkelstcin A , Kingslcy L , Spcro JA, Lewis JH. 1986update of HIV scroprevalence, seroconversion, AIDS incidence,and immunologic correlates of HIV infection in patients with he­mophilia A and B. Blood 1987;70:786-90.16. Gocdcrt J J , Kcssler CM, Aledort LM, et al. A prospective studyof human immunodeficiency virus type 1 infection and the de­velopment of AIDS in subjects with hemophilia. N Engl J Med1989;321:1141-8.17. Risks associated with human parvovirus B19 infection. MMWRMorb Mortal Wkly Rep 1989;3.8:81-8,93-7.18. Frickhofen N, Abkowitz JL, Safford M, et ai. Persistent B19parvovirus infection in patients infected with human immunode­ficiency virus type 1 (HIV-1): a treatable cause of anemia inAIDS. Ann Intern Med 1990;113:926-33.19. Mortimer PP, Luban NL, Ke lie her JF, Cohen BJ, Transmissionof scrum parvovirus-like virus by clotting-factor concentrates. Lancet1983;2:482-4.20. Morfini M, Longo G, Rossi Fcrrini P, cl al. Hypoplastic anemiain a hemophiliac first infused with a solvent/detergent treated fac­tor VIII concentrate: the role of human B19 parvovirus (letter).Am J Hcmalol 1992;39:149-50.21. Azzi A , Ciappi S , Zakvrzewska K, Morfini M, Mariani G, Man-nucei PM. Human parvovirus B19 infection in hemophiliacs firstinfused with two high-purity, virally attenuated factor VIII con­centrates. Am J Hematol 1992;39:228-30.22. Kasper CK. Thromboembolic complications. Thromb Diath Hac-morrh 1975;33:640-4.23. Lusher JM. Thrombogenicity associated with factor IX complexconcentrates. Semin Hematol 1991 ;2S(3 Suppl 6):3-5.24. Chavin SI, Siegel DM, Rosco T A Jr, Olson JP, Acute myocardialinfarction during treatment with an activated prothrombin complexconccntrate in a patient with factor VIII deficiency and a factorVIII inhibitor. Am J Med 1988;85:245-9.25. Mannucci PM, Bauer KA, Gringeri A, ct al. No activation of thecommon pathway of the coagulation cascade after a highly puri­fied factor IX concentrate. Br J Haematol 1991;79:606-11.26. Menachc D, Behre HE, Orthner CL, et al. Coagulation factor IXconcentrate: method of preparation and assessment of potential invivo thrombogenicity in animal models. Blood 1984;64:1220-7.27. Kim HC, Matts L , Eisele J , Czachur M , Saidi P. Monoclonalantibody-purified factor IX—comparative thrombogenicity to pro­thrombin complex concentrate, Semin Hematol 1991;28(3 Suppl6): 15-9.28. Aronson DL, Finlayson JS. Direct and indirect effects of chronicpiasma protein infusion. In: Fratantoni JC, Aronson DL, cds.Unsolved therapeutic problems in hemophilia. US Dcpt of Health,Education, and Welfare publication No. (N1H) 77-1089, 1976:93-1 0 1 .29. Stein SF, Evalt BL, McDougal JS, ct al. A longitudinal study ofpatients wiih hemophilia: immunologic correlates of infection withHTLV-III/LAV and other viruses. Blood 1985;66:973-9,30. Cuthben RJ, Ludlam CA, Steel CM, Beatson D, Pcuthcrcr JF, Im­munological studies in HIV seronegative haemophiliacs: relation­ships to blood product therapy. Br J Haemaiol 1992;80:364-9.31. Evans JA, Pasi KJ, Williams MD, Hill FG, Consistently normalCD4 + , C D 8 + levels in haemophilic boys only treated with avirally safe factor VIII concentrate (BPL 8Y). Br J Haematol1991;79:457-61.32. Thorpe R , Dilger P, Dawson NJ, Barrowciiffc T W . Inhibition ofintcrlcukin-2 secretion by factor VIII concentrates: a possible causeof immunosuppress ion in haemophi l iacs , Br J Haematol1989;71:387-91.33. Pasi KJ, Hill FG. In vitro and in vivo inhibition of monocytephagocytic function by factor VIII concentrates: correlation withconcentratc purity. Br J Haematol 1990;76:88-93,34. Madhok R , Smith J , Jenkins A , Lowe GD. T cell sensitization tofactor VIII in haemophilia A? Br J Haematol 1991;79:235-8.35. Eibl M M , Ahmad R, Wolf HM, Linnau Y , Gotz E , MannhalterJW. A component of factor VIII preparations which can be sep­arated from factor VIII activity down modulates human monocytefunctions. Blood 1987;69:1153-60,36. Vcrmot-Desroches C , Rigal D, Blourde C , Bernaud J . Immuno­suppressive property of a very high purity antihacmophilic prep­aration: a low molecular weight component inhibits an early stepof PHA induced cell activation. Br J Haematol 1992;80:370-7.37. Levine PH. Factor V1II:C purified from plasma via monoclonalantibodies: human studies, Semin Hematol I988;25(2 Suppl I):38-41.38. Cash JD . High potency factor VIII concentrates: value not proved?BMJ 1991;303:633-4.39. Goldsmith J M , Deutsche J , Tang M , Green D. CD4 cells inHIV-1 infected hemophiliacs: effect of factor VIII concentrates.Thromb Hacmost 1991;66:415-9.40. De Biasi R, Rocino A , Miraglia E, Mastrullo L, Quirino AA.The impact of a very high purity factor VIII concentrate on theimmune system of human immunodeficiency virus-infected he­mophiliacs: a randomized, prospective, two-year comparison withan intermediate purity concentrate. Blood 1991;78:1919-22.41.. Mannucci PM, Gringeri A , de Biasi R, Baudo F, Morfini M,Ciavarclla N. Immune status of asymptomatic HIV-infcctcd he­mophiliacs: randomized, prospective, two-year comparison oftreatment with a high-purity or an intermediate-purity factor VIIIconcentrate. Thromb Hacmost 1992;67:310-3.42. While G C II, McMillan C W , Kingdon HS, Shoemaker CB. Useof recombinant antihemophilic factor in the treatment of two pa­tients with classic hemophilia. N Engl J Med 1989;320:166-70,43. Schwartz RS, Abildgaard CF, Aledort LM, ct al. Human recom­binant DNA-derivcd antihemophilic factor (factor VIII) in thetreatment of hemophilia A . Recombinant Factor VIII Study Group.N Engl J Med 1990;323:1800-5.44. Horowitz B, Wicbe ME, Lippin A , Stryker MH. Inactivation ofviruses in labile blood derivatives. 1. Disruption of lipid-envclopcdviruses by tri(n-butyl)phosphate detergent combinations. Trans­fusion 1985;25:516-22.45. Horowitz B, Wiebc ME, Lippin A, Vandcrsandc J , Stryker MH,Inactivation of viruses in labile blood derivatives, 11, Physicalmethods. Transfusion 1985;25:523-7.46. Gompcrts E D . Procedures for the inactivation of viruses in clottingfactor concentrates. Am J Hematol 1986;23:295-305.47. Thomas DP. Reducing the risk of virus transmission by bloodproducts. Br J Haematol 1988;70:393-5.48. Ways to reduce the risk of transmission of viral infections byplasma and plasma products: a comparison of methods, their ad­vantages and disadvantages. Vox Sang 1988;54:228-45.49. Brcttler DB, Levine PH. Factor conccntrates for treatment of he­mophilia; which one to choose? Blood 1989;73:2067-73.50. Roberts HE, Eberst ME, The molecular biology of classic he­mophilia and a review of factor VIII concentrates. In: Spivak JL,Bell WR, Ness PM, Qucsenberry PJ, Wiernik PH, cds. The yearbook of hematology. St Louis: Mosby Year Book, 1992:121-44, 51 . Heinrich D, Kotitschkc R, Bcrthold H, Clinical evaluation of thehepatitis safety of a bcta-propiolaelone/ultraviolet treated factorIX concentrate (PPSB). Thromb Res 1982;28:75-83.52. Schimpf K, Mannucci PM, Krcutz W , ct al. Absence of hepatitisafter treatment with a pasteurized factor VIII concentrate in pa­tients with hemophilia and n o previous transfusions. N Enel JMed 1987;316:918-22.53. Colombo M, Mannucci PM, Carnclli V, Savidge GF, GazengclC, Schimpf K. Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancct 1985;2:1-4.54. Medical Bulletin # 9 : Chapter Advisory # 1 2 . Medical and Sci­entific Advisory Council. New York: National Hemophilia Foun­dation, October 22, 1983.55. Skidmore SJ, Pasi KJ, Mawson SJ, Williams MD, Hill FG. Se­rological evidence that dry heating of clotting factor concentratesprevents transmission of non-A, non-B hepatitis. J Med Virol1990;30:50-2.